JP2018511642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511642A5 JP2018511642A5 JP2017554375A JP2017554375A JP2018511642A5 JP 2018511642 A5 JP2018511642 A5 JP 2018511642A5 JP 2017554375 A JP2017554375 A JP 2017554375A JP 2017554375 A JP2017554375 A JP 2017554375A JP 2018511642 A5 JP2018511642 A5 JP 2018511642A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- composition
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149349P | 2015-04-17 | 2015-04-17 | |
| US62/149,349 | 2015-04-17 | ||
| PCT/US2016/028179 WO2016168858A1 (en) | 2015-04-17 | 2016-04-18 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018511642A JP2018511642A (ja) | 2018-04-26 |
| JP2018511642A5 true JP2018511642A5 (enExample) | 2019-04-25 |
Family
ID=55854800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554375A Pending JP2018511642A (ja) | 2015-04-17 | 2016-04-18 | 癌を治療するための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180098959A1 (enExample) |
| EP (1) | EP3283070A1 (enExample) |
| JP (1) | JP2018511642A (enExample) |
| KR (1) | KR20170137833A (enExample) |
| CN (1) | CN107820426A (enExample) |
| AU (1) | AU2016249158A1 (enExample) |
| BR (1) | BR112017022296A2 (enExample) |
| CA (1) | CA2983013A1 (enExample) |
| EA (1) | EA201792286A1 (enExample) |
| HK (1) | HK1250943A1 (enExample) |
| IL (1) | IL255016A0 (enExample) |
| MX (1) | MX2017013358A (enExample) |
| PH (1) | PH12017501881A1 (enExample) |
| SG (1) | SG11201708505WA (enExample) |
| TW (1) | TW201709905A (enExample) |
| WO (1) | WO2016168858A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736564A1 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| SG11201508358RA (en) | 2013-04-09 | 2015-11-27 | Boston Biomedical Inc | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736564A1 (en) * | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| SG11201508358RA (en) * | 2013-04-09 | 2015-11-27 | Boston Biomedical Inc | 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer |
-
2016
- 2016-04-18 MX MX2017013358A patent/MX2017013358A/es unknown
- 2016-04-18 BR BR112017022296A patent/BR112017022296A2/pt not_active Application Discontinuation
- 2016-04-18 EP EP16723855.9A patent/EP3283070A1/en not_active Withdrawn
- 2016-04-18 HK HK18110437.0A patent/HK1250943A1/zh unknown
- 2016-04-18 TW TW105112095A patent/TW201709905A/zh unknown
- 2016-04-18 EA EA201792286A patent/EA201792286A1/ru unknown
- 2016-04-18 SG SG11201708505WA patent/SG11201708505WA/en unknown
- 2016-04-18 CA CA2983013A patent/CA2983013A1/en not_active Abandoned
- 2016-04-18 AU AU2016249158A patent/AU2016249158A1/en not_active Abandoned
- 2016-04-18 JP JP2017554375A patent/JP2018511642A/ja active Pending
- 2016-04-18 KR KR1020177032742A patent/KR20170137833A/ko not_active Withdrawn
- 2016-04-18 CN CN201680032521.2A patent/CN107820426A/zh active Pending
- 2016-04-18 WO PCT/US2016/028179 patent/WO2016168858A1/en not_active Ceased
- 2016-04-18 US US15/567,070 patent/US20180098959A1/en not_active Abandoned
-
2017
- 2017-10-15 IL IL255016A patent/IL255016A0/en unknown
- 2017-10-18 PH PH12017501881A patent/PH12017501881A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506392A5 (enExample) | ||
| ES2561495T3 (es) | Régimen de tratamiento que utiliza neratinib contra cáncer de mama | |
| JP2020514311A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2014509657A5 (enExample) | ||
| JP2017505321A5 (enExample) | ||
| JP2018511643A5 (enExample) | ||
| Giancola et al. | Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? | |
| WO2017037292A1 (en) | Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer | |
| JP2018511642A5 (enExample) | ||
| JP2018525358A5 (enExample) | ||
| JP2018519324A5 (enExample) | ||
| JP2016529285A5 (enExample) | ||
| Park et al. | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | |
| JP2012522837A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| JP2018502913A5 (enExample) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| MX2022004739A (es) | Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo. | |
| TW201313228A (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| JP2018514557A5 (enExample) | ||
| JP2018519300A5 (enExample) |